Radiomitigators: Breakthroughs in Post-Radiation Recovery
Antioxidants · 18.03.2026 · 15 (3) · 381
DOI: 10.3390/antiox15030381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 18.03.2026. Verfasst von Elena Obrador und 5 weiteren Autor:innen. Beteiligte Einrichtung: Scientia BioTech, 46002 Valencia, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 1263 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MCIN/AEI/10.13039/501100011033, MICIU/AEI/10.13039/501100011033.
Abstract (Originalsprache)
Ionizing radiation (IR) exposure poses a significant biomedical challenge in clinical, occupational, and emergency contexts, highlighting the urgent need for effective medical countermeasures against acute radiation syndrome (ARS) and delayed effects of radiation exposure (DEARE). Depending on the timing of administration, radiation countermeasures are classified as radioprotectors, radiomitigators, or therapeutics. Among these, radiomitigators offer a critical advantage by attenuating IR-induced damage when administered after exposure, thereby expanding their applicability in unanticipated radiation incidents. This review provides an overview of the pathophysiological mechanisms underlying IR-induced injury and summarizes the current FDA-approved radiation countermeasures. It then focuses on radiomitigators that have demonstrated efficacy in preclinical animal models, together with available evidence from clinical studies, emphasizing their translational potential for both emergency preparedness and oncological settings. We examine routes of administration and key mechanisms of action, including modulation of oxidative and nitrosative stress, enhancement of DNA damage response pathways, preservation of mitochondrial function, regulation of inflammatory and immune signaling, attenuation of fibrotic remodeling, maintenance of vascular integrity, and promotion of tissue regeneration and repair. Finally, challenges associated with clinical translation and strategies to optimize radiomitigators for the management of radiation-induced injury are discussed. By integrating these insights and consolidating existing knowledge, this review aims to guide basic and clinical research toward more effective radiomitigative strategies and combination therapies to improve survival, limit tissue damage, and preserve long-term quality of life in individuals exposed to IR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Scientia BioTech, 46002 Valencia, Spain.
- Cell Pathophysiology Unit, Department of Physiology, Faculty of Medicine & Odontology, University of Valencia, 46010 Valencia, Spain.
- IIS and Radioprotection Service, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain.
ORCID-Profile: Elena Obrador, José M Estrela, Paz Moreno-Murciano, Alegría Montoro, María Oriol-Caballo
Förderung
- MCIN/AEI/10.13039/501100011033
- MICIU/AEI/10.13039/501100011033
Zitieren
APA
Obrador, E., Estrela, J. M., López-Blanch, R., Moreno-Murciano, P., Montoro, A., & Oriol-Caballo, M. (2026). Radiomitigators: Breakthroughs in Post-Radiation Recovery. Antioxidants, 15(3), 381. https://doi.org/10.3390/antiox15030381
Vancouver
Obrador E, Estrela JM, López-Blanch R, Moreno-Murciano P, Montoro A, Oriol-Caballo M. Radiomitigators: Breakthroughs in Post-Radiation Recovery. Antioxidants. 2026;15(3):381. doi:10.3390/antiox15030381
BibTeX
@article{Obrador2026,
author = {Obrador, Elena and Estrela, José M and López-Blanch, Rafael and Moreno-Murciano, Paz and Montoro, Alegría and Oriol-Caballo, María},
title = {Radiomitigators: Breakthroughs in Post-Radiation Recovery},
journal = {Antioxidants},
year = {2026},
volume = {15},
number = {3},
pages = {381},
doi = {10.3390/antiox15030381}
}
EUVIMED